ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Brucellin Aquilon solution for injection for pigs

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

One dose (0.1 ml) contains:

Active substance:

Concentrated purified protein extract of *Brucella abortus* strain AQ1302: ≥ 1 RP*

*relative potency compared to a reference batch tested in sensitised guinea pigs.

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Solution for injection.
Clear and colourless to yellowish solution without particles.

4. CLINICAL PARTICULARS

4.1 Target species

Pigs.

4.2 Indications for use, specifying the target species

For *in vivo* diagnosis of *Brucella*-infected pigs through a positive skin reaction after a positive serological *Brucella* test.

Brucellin Aquilon has been specifically designed as a second line diagnostic test to differentiate *Brucella*-infected pigs, from the age of 5 months, from the *Brucella*-free pigs having given false positive serological reactions (FPSR) in brucellosis serological tests based on anti-O-PS antibodies (e.g. Rose Bengal).

4.3 Contraindications

None.

4.4 Special warnings for each target species

Do not use this veterinary medicinal product in pigs treated with anti-inflammatory medicinal products being still active.

4.5 Special precautions for use

Special precautions for use in animals:

Not applicable.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

4.6 Adverse reactions (frequency and seriousness)

None.

4.7 Use during pregnancy, lactation or lay

Can be used during pregnancy and lactation.

4.8 Interaction with other medicinal products and other forms of interaction

No information is available on the safety and efficacy of this immunological veterinary medicinal product when used with any other veterinary medicinal product. A decision to use this immunological veterinary medicinal product before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

4.9 Amounts to be administered and administration route

Route of administration

Intradermal use.

Dose:
A single administration of one dose (0.1 ml) per animal.

Method of administration

- Select non-pigmented areas of the skin preferably in the perianal region close to the tail.
- Clean the selected area with neutral soap and dry with absorbent paper.
- If desired to facilitate the reading of the reaction, mark a circle of 10 cm of diameter with a permanent market at the inoculation site.
- Use an injection device suitable for intradermal injection of veterinary medicinal products adaptable to 0.1 volume injection and with a needle of 1/8'' (4 mm) length and a calibre of 22G (0.70 mm).
- Inoculate intradermally 0.1 ml of Brucellin Aquilon.
- A small papule is observed after inoculation.

Reaction reading

- After 48 hours, observe and palpate the inoculation point.
- The reading is based upon the presence or absence of a clear skin reaction.
- A positive reaction is defined as any inflammatory reaction and/or haemorrhage detected at the inoculation site with any of these characteristics:
  - Skin discolouration (from reddish to almost black colour)
  - Papule (swelling > 0.5-1 cm diameter)
  - Nodule (evident local swelling bigger than 1 cm diameter), accompanied or not with skin discolouration.

  A hardly visible small red point due to the needle puncture can be observed in some animals and should not be considered as a positive reaction.
  Reactions have been observed up to 72 hours.

4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary

No adverse reactions have been observed after administration of a double dose.

4.11 Withdrawal period

Zero days.

5. IMMUNOLOGICAL PROPERTIES

Pharmacotherapeutic group: In vivo diagnostic preparations for pigs.

ATC vet code: QI09AR

The active substance is based on a concentrated purified protein obtained from the cytosol of the strain *Brucella abortus* AQ1302, which has been genetically modified to carry a disrupted *per* (perosamine synthase) gene.

Brucellin Aquilon did induce neither sensitisation nor positive serological results in brucellosis O-PS serological tests even after four repeated administrations.

Brucellin Aquilon did not induce noticeable anergy when a second skin test was performed 1 to 4 weeks after the first one.

Brucellin Aquilon skin test provided 100% diagnostic specificity in pigs from *Brucella*-free farms and in *Yersinia enterocolitica* O:9 (bacterium causing most often FPSR) experimentally sensitised pigs.

Brucellin Aquilon skin test provided 100% of diagnostic sensitivity in *B. suis*-related aborted sows while the sensitivity was 80% in sows at various reproductive stages. The sensitivity was not investigated in other categories of pigs.

The results of the skin tests in individual animals should be carefully interpreted, together with clinical and epidemiological factors to confirm the absence or the presence of the infection in the farm/epidemiological unit.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Sodium chloride
Water for injections

6.2 Major incompatibilities

Not applicable.

6.3 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 2 years.
Shelf life after first opening the immediate packaging: use immediately.

6.4. Special precautions for storage

Store and transport refrigerated (2 ºC – 8 ºC).
Protect from light.

6.5 Nature and composition of immediate packaging

Multi-dose type I glass vial of 3 ml with perforable butyl rubber stopper and sealed with flip-off aluminium seals, containing 2.5 ml of the veterinary medicinal product (25 doses).
Cardboard box containing 1 vial.

6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

Aquilón CyL S.L.
Facultad de Veterinaria
Campus de Vegazana s/n
24007 León
Spain

8. MARKETING AUTHORISATION NUMBER(S)

EU/2/22/291/001

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 26/01/2023

10 DATE OF REVISION OF THE TEXT

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (http://www.ema.europa.eu/).

PROHIBITION OF SALE, SUPPLY AND/OR USE

Any person intending to manufacture, import, possess, sell, supply and use this veterinary medicinal product may need to consult the relevant Member State's competent authority on the current brucellin diagnostic policies, as these activities may be prohibited in a Member State on the whole or part of its territory pursuant to national legislation.

ANNEX II

A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

C. STATEMENT OF THE MRLs

D. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturer of the biological active substance

CZ Vaccines S.A.U
A Relva, Torneiros s/n
36410 O Porriño (Pontevedra) - Spain.

Name and address of the manufacturer responsible for batch release

CZ Vaccines S.A.U
A Relva, Torneiros s/n
36410 O Porriño (Pontevedra) - Spain.

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Veterinary medicinal product subject to prescription.

Official control authority batch release is required for this product.

C. STATEMENT OF THE MRLs

The active substance being a principle of biological origin intended to diagnose a state of immunity is not within the scope of Regulation (EC) No 470/2009.

The excipients listed in section 6.1 of the SPC are allowed substances for which table 1 of the annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required or considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this veterinary medicinal product.

D. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

· CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT

For use by veterinary surgeons only.

ANNEX III

LABELLING AND PACKAGE LEAFLET

A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGE

CARDBOARD BOX

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Brucellin Aquilon solution for injection for pigs

2. STATEMENT OF ACTIVE SUBSTANCES

One dose (0.1 ml) contains:
Concentrated purified protein extract of *Brucella abortus* strain AQ1302: ≥ 1 RP (*).
*relative potency studied in sensitized guinea pigs.

3. PHARMACEUTICAL FORM

Solution for injection.

4. PACKAGE SIZE

2.5 ml (25 doses)

5. TARGET SPECIES

Pigs

6. INDICATION(S)

7. METHOD AND ROUTE(S) OF ADMINISTRATION

Intradermal use.
Read the package leaflet before use.

8. WITHDRAWAL PERIOD(S)

Withdrawal period: Zero days.

9. SPECIAL WARNING(S), IF NECESSARY

10. EXPIRY DATE

EXP
Once opened use immediately.

11. SPECIAL STORAGE CONDITIONS

Store and transport refrigerated.
Protect from light.

12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

Dispose of waste material in accordance with local requirements.

13. THE WORDS "FOR ANIMAL TREATMENT ONLY" AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE

For animal treatment only. To be supplied only on veterinary prescription.

The import, possession, sale, supply and/or use of this veterinary medicinal product may be prohibited in a Member State on the whole or part of its territory, see package leaflet for further information.

14. THE WORDS "KEEP OUT OF THE SIGHT AND REACH OF CHILDREN"

Keep out of the sight and reach of children.

15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Aquilón CyL S.L.
Facultad de Veterinaria
Campus de Vegazana s/n
24007 León
Spain

16. MARKETING AUTHORISATION NUMBER(S)

EU/2/22/291/001

17. MANUFACTURER'S BATCH NUMBER

Batch

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

VIAL LABEL 2.5 ML

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Brucellin Aquilon solution for injection for pigs

2. QUANTITY OF THE ACTIVE SUBSTANCE(S)

One dose (0.1 ml) contains:
Concentrated purified protein extract of *Brucella abortus* strain AQ1302: ≥1 RP (*).
*relative potency studied in sensitized guinea pigs

3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES

2.5 ml (25 doses)

4. ROUTE(S) OF ADMINISTRATION

Intradermal use.

5. WITHDRAWAL PERIOD(S)

Withdrawal period: Zero days.

6. BATCH NUMBER

Batch

7. EXPIRY DATE

EXP
Once opened use immediately.

8. THE WORDS "FOR ANIMAL TREATMENT ONLY"

For animal treatment only.

B. PACKAGE LEAFLET

PACKAGE LEAFLET:
Brucellin Aquilon solution for injection for pigs

1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT

Marketing authorisation holder:
Aquilón CyL S.L.
Facultad de Veterinaria
Campus de Vegazana s/n
24007 León
Spain

Manufacturer responsible for batch release:
CZ Vaccines S.A.U
A Relva, Torneiros s/n
36410 O Porriño (Pontevedra) - Spain.

2. NAME OF THE VETERINARY MEDICINAL PRODUCT

Brucellin Aquilon solution for injection for pigs

3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)

One dose (0.1 ml) contains:

Concentrated purified protein extract of *Brucella abortus* strain AQ1302: ≥ 1 RP*.
*relative potency studied in sensitised guinea pigs

Clear and colourless to yellowish solution without particles.

4. INDICATION(S)

For *in vivo* diagnosis of *Brucella*-infected pigs through a positive skin reaction after a positive serological *Brucella* test.

Brucellin Aquilon has been specifically designed as a second line diagnostic test to differentiate *Brucella*-infected pigs, from the age of 5 months, from the *Brucella*-free pigs having given false positive serological reactions (FPSR) in brucellosis serological tests based on anti-O-PS antibodies (e.g. Rose Bengal).

5. CONTRAINDICATIONS

None.

6. ADVERSE REACTIONS

None.

If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon.

7. TARGET SPECIES

Pigs.

8. DOSAGE FOR EACH SPECIES, ROUTE AND METHOD OF ADMINISTRATION

Dose: 0.1 ml

Intradermal use via injection in the perianal area.

9. ADVICE ON CORRECT ADMINISTRATION

Veterinary medicinal product administration:

- Select non-pigmented areas of the skin preferably in the perianal region close to the tail.
- Clean the selected area with neutral soap and dry with absorbent paper.
- If desired to facilitate the reading of the reaction, mark a circle of 10 cm of diameter with a permanent market at the inoculation site.
- Use an injection device suitable for intradermal injection of veterinary medicinal products adaptable to 0.1 volume injection and with a needle of 1/8'' (4 mm) length and a calibre of 22G (0.70 mm)
- Inoculate intradermally 0.1 ml of Brucellin Aquilon.
- A small papule is observed after inoculation.

Reaction reading:

- After 48 hours, observe and palpate the inoculation point.
- The reading is based upon the presence or absence of a clear skin reaction.
- A positive reaction is defined as any inflammatory reaction and/or haemorrhage detected at the inoculation site with any of these characteristics:
  - Skin discolouration (from reddish to almost black colour)
  - Papule (swelling > 0.5-1 cm diameter)
  - Nodule (evident local swelling bigger than 1 cm diameter), accompanied or not with skin discolouration.

  A hardly visible small red point due to the needle puncture can be observed in some animals and should not be considered as a positive reaction. Reactions have been observed up to 72 hours.

10. WITHDRAWAL PERIOD(S)

Zero days.

11. SPECIAL STORAGE PRECAUTIONS

Keep out of the sight and reach of children.
Store and transport refrigerated (2 °C – 8 °C).
Protect from light.
Shelf life after first opening the container: use immediately.

12. SPECIAL WARNING(S)

Special warnings for each target species:
Do not use this product in pigs treated with anti-inflammatory medicinal products being still active.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:
In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

Pregnancy and lactation:
Can be used during pregnancy and lactation.

Interaction with other medicinal products and other forms of interaction:
No information is available on the safety and efficacy of this immunological veterinary medicinal product when used with any other veterinary medicinal product. A decision to use this immunological veterinary medicinal product before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY

Ask your veterinary surgeon how to dispose of medicines no longer required. These measures should help to protect the environment.

14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (http://www.ema.europa.eu/).

15. OTHER INFORMATION

Pack size:

Cardboard box with one vial of 25 doses (2.5 ml).

Immunological properties

The active substance is based on a concentrated purified protein obtained from the cytosol of the strain *Brucella abortus* AQ1302, which has been genetically modified to carry a disrupted *per* (perosamine synthase) gene.

Brucellin Aquilon did induce neither sensitisation nor positive serological results in brucellosis O-PS serological tests even after four repeated administrations.

Brucellin Aquilon did not induce noticeable anergy when a second skin test was performed 1 to 4 weeks after the first one.

Brucellin Aquilon skin test provided 100% diagnostic specificity in pigs from *Brucella*-free farms and in *Yersinia enterocolitica* O:9 (bacterium causing most often FPSR) experimentally sensitised pigs.

Brucellin Aquilon skin test provided 100% of diagnostic sensitivity in *B. suis*-related aborted sows while the sensitivity was 80% in sows at various reproductive stages. The sensitivity was not investigated in other categories of pigs.

The results of the skin tests in individual animals should be carefully interpreted, together with clinical and epidemiological factors to confirm the absence or the presence of the infection in the farm/epidemiological unit.